United Kingdom · Question · Written question
UIN 62793
NHS: Drugs
Original
Introduced
13 October 2022
Last action
25 October 2022 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
25 October 2022
Summary
To ask the Secretary of State for Health and Social Care, if she will make a comparative estimate of the annual savings that (a) unbranded generic, (b) branded generic and (c) biosimilar medicines have contributed to the NHS drug bill compared to branded
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
13 October 2022
Written question
To ask the Secretary of State for Health and Social Care, if she will make a comparative estimate of the annual savings that (a) unbranded generic, (b) branded generic and (c) biosimilar medicines have contributed to the NHS drug bill compared to branded
Source: Commons
25 October 2022
Answer
The current Voluntary Scheme for Branded Medicines Pricing and Access expenditure forecast assumes that average spend at patent expiry will decrease by 70% for a non-biologic medicine or 45% for a biologic medicine. The Secretary of State has also commiss...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2022-10-13/62793
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1521789
- uk · wq-1521789 · source updated 25 October 2022